Fibromyalgia syndrome: A discussion of the syndrome and pharmacotherapy

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages 418-439

  Smith, Howard S ^a   Barkin, Robert L ^b,c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

central sensitivity syndromes; fatigue; fibromyalgia; pain

Indexed keywords

ALFENTANIL; AMITRIPTYLINE; AMOXAPINE; BROMOCRIPTINE; BUSPIRONE; CABERGOLINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CYCLOBENZAPRINE; CYTOCHROME P450 ISOENZYME; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABNORMAL THINKING; AEROBIC EXERCISE; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY; APPETITE; ARTHRALGIA; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; BLADDER IRRITATION; BLOOD PRESSURE; BLURRED VISION; CARDIOVASCULAR EFFECT; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DYSPEPSIA; ECCHYMOSIS; EUPHORIA; FATIGUE; FEEDBACK SYSTEM; FIBROMYALGIA; FIBROMYALGIA SYNDROME; FIBROMYLAGIA IMPACT QUESTIONNAIRE; FOCAL EPILEPSY; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HUMAN; HYDROTHERAPY; HYPERALGESIA; HYPERHIDROSIS; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; INTERSTITIAL CYSTITIS; IRRITABILITY; IRRITABLE COLON; LIBIDO DISORDER; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MENTAL CONCENTRATION; MUSCLE TRAINING; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; NIGHTMARE; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PAIN; PAIN ASSESSMENT; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; PR INTERVAL; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; QUALITY OF LIFE; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SLEEP DISORDER; SOMNOLENCE; STROKE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYNCOPE; TACHYCARDIA; TEMPOROMANDIBULAR JOINT DISORDER; THROMBOCYTOPENIA; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA; ANALGESIA; COMPLICATION; KINESIOTHERAPY; MULTIMODALITY CANCER THERAPY;

COGNITIVE THERAPY; COMBINED MODALITY THERAPY; EXERCISE THERAPY; FIBROMYALGIA; HUMANS; PAIN; PATIENT EDUCATION AS TOPIC; QUALITY OF LIFE; PAIN MANAGEMENT;

EID: 77955013068     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181df8e1b     Document Type: Review

References (110)

1. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromylagia in the general population. Arthritis Rheum. 1995;38:19-28.
2. Miedema HS, van der Linden SM, Rasker JJ, et al. National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. Br J Rheumatol. 1998;37:555-561.
3. Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther. 2006;8:218.
4. Arnold LM, Hudson JL, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50:944-952.
5. Cohen H, Buskila D, Neumann L, et al. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety related personality traits. Arthritis Rheum. 2002;46:845-847.
6. GursoyS.Absenceof associationof the serotonintransporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol. 2002;21:194-197.
7. Gursoy S, Erdal E, Herken H, et al. Significance of catechol-O- methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003;23:104-107. (Pubitemid 36712983)
8. Buskila D, Cohen H, Neumann L, et al. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship personality traits. Mol Psychiatry. 2004;9:730-731.
9. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
10. Jones J, Rutledge DN, Jones KD, et al. Self-assessed physical function levels of women with fibromyalgia: a national survey. Womens Health Issues. 2008;18: 406-412.
11. Carmona L, Ballina J, Gabriel R, et al. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis. 2001;60:1040-1045.
12. Bernard AL, Prince A, Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res. 2000;13:42-50.
13. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol. 1993; 20:475-479.
14. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-172.
15. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6-21.
16. Orellana C, Casado E, MasipM, et al. Sexual dysfunction in fibromyalgia patients. Clin Exp Rheumatol. 2008;26:663-666.
17. Kalichman L.Association between fibromyalgia and sexual dysfunction inwomen. Clin Rheumatol. 2009;28:365-369.
18. Staud R. Fibromyalgia syndrome. In: SmithHS, ed. Current Therapy in Pain. Philadelphia: Elsevier; 2009:233-240.
19. McCarberg B, Barkin RL,Wright JA, et al. Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome. Am J Ther. 2003;10:176-192.
20. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600-610.
21. Wolfe F, Clauw D, Fitzcharles MA, et al. Clinical Diagnostic and Severity Criteria for Fibromyalgia. Presentation 567. ACR/ARHP ScienticMeeting; Philadelphia, PA; October 18, 2009.
22. Prins MA, Woertman L, Kool MB, et al. Sexual functioning of women with fibromyalgia. Clin Exp Rheumatol. 2006;24:555-561.
23. Shaver JL, Wilbur J, Robinson FP, et al. Women's health issues with fibromyalgia syndrome. J Women's Health (Larchmt). 2006;15:1035-1045.
24. Rosenbaum TY. Musculoskeletal pain and sexual function in women. J Sex Med. 2010;7:645-653.
25. Orellana C, Gratacó s J, Galisteo C, et al. Sexual dysfunction in patients with fibromyalgia. Curr Rheumatol Rep. 2009;11:437-442.
26. Vaerøy H, Helle R, Førre O, et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988;32:21-26.
27. Russell IJ, OrrMD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593-1601.
28. Liu Z, Welin M, Bragee B, et al. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides. 2000;21:853-860.
29. Bradley LA, Alarcóm GS. Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia? Arthris Rheum. 1999;42:2731-2732.
30. Russell IJ, Vaerøy H, Javors M, et al. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-556.
31. Sarchielli P, Mancini ML, Floridi A, et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain. 2007;8:737-745.
32. Bennett RM, Friend R, Jones KD, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11:R120.
33. Häuser W, Bernardy K, Ucxeyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a metaanalysis. JAMA. 2009;301:198-209.
34. Hansten PD, Horn JR. The Top 100 Drug Interactions-A Guide to Patient Management. Freeland, WA: H&H Publications, LLP, 2010.
35. Wickersham RM. Senior Managing editor, Drug Facts and comparisons. E-answers 2010. Wolter Kluwer Health, Inc. Available at: http://www. factsandcomparisons.com/ facts-comparison-online.aspx. Accessed May 25, 2010.
36. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med. 2007; 8:S63-S74.
37. Beebe FA, Barkin RL, Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther. 2005;12:151-171.
38. Brown DV, Heller F, Barkin R. Anticholinergic syndrome after anesthesia: a case report and review. Am J Ther. 2004;11:144-153.
39. Barkin RL. Extended-release tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther. 2008;15:157-166.
40. Barkin RL. Duloxetine: A pharmacological overview. Pain Medicine Network. 2007;22:8-11.
41. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974-2984.
42. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.
43. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebocontrolled, fixed-dose trial. Pain. 2008;136:432-444.
44. Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. International Journal of General Medicine. 2008;1:91-102.
45. Arnold LM, Clauw DJ, Wohlreich MM, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry. 2009;11:237-244.
46. Barkin RL. Milnacipran: a pharmacotherapeutic-focused brief review. Pain Medicine Network. 2009;23:8-9.
47. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19:S27-S35.
48. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30:1988-2004.
49. Mease PJ, Clauw DJ, Gemdreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia, a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36:398-409.
50. Goldenberg DL, Clauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med. 2010; 11:180-194.
51. Chwieduk CM, McCormack PL. Milnacipran: in fibromyalgia. Drugs. 2010;70:99-108.
52. Mease P, Palmer RH, Wang Y, et al. Milnacipran improves fatigue in fibromyalgia: pooled analyses from 3 randomized, placebo-controlled clinical Trials [Abstract]. Arthritis Rheum. 2009;60:1423.
53. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research. 2007;73:137-150.
54. Barkin RL. Pregabalin: a critical review. Pain Medicine Network. 2008;24:8-9.
55. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. American Journal of Health-System Pharmacy. 2007;64:1475-1482.
56. Barkin RL.Methadone: a novel and potentially hazardous opioid analgesic. Pain Medicine Network. 2006;21:4-11.
57. US Food and Drug Administration (2008, January 31). FDA Alert: Information for Healthcare Professionals Suicidality and Antiepileptic Drugs. Available at: www.fda.gov/Cder/ Drug/InfoSheets/HCP/antiepilepticsHCP.htm. Accessed April 10, 2008.
58. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo controlled trial. Arthritis Rheum. 2005;52:1264-1267.
59. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792-805.
60. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502-514.
61. Pauer L, Danneskiold-Samsoe B, Jespersen A, et al. Pregabalin for management of fibromyalgia (FM): a 14-week, randomized, double-blind, placebo-controlled monotherapy trial (study A0081100). Ann Rheum Dis. 2008;67:S256.
62. Häuser W, Bernardy K, Ucxeyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin-a meta-analysis of randomized controlled trials. Pain. 2009;145:69-81.
63. Barkin RL. Tapentadol: a pharmacotherapeutic-focused brief review. Pain Medicine Network. 2009;24:8-11.
64. Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg. 2008;107:2048-2055.
65. Daniels SE, Upmalis D, Okamoto A, et al A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25: 765-776.
66. Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009;25:1095-1104.
67. Etropolski MS, Okamoto A, Shapiro DY, et al. Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician. 2010;13:61-70.
68. Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manage. 2008;14:145-152.
69. Barkin RL. Drug metabolism. Pain Medicine Network. 2007;22:6-7.
70. Barkin RL. Incorporation of science and clinical medicine in the process of patient-specific and patient-centered, patient focused prescribing and personalized patient care. Pain Medicine Network. 2008;23:4-9.
71. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002;18:S76-S82.
72. Jones KD, Liptan GL. Exercise interventions in fibromyalgia: clinical applications from the evidence. Rheum Dis Clin N Am. 2009;35:373-391.
73. Alentorn-Geli E, Padilla J, Moras G, et al. Six weeks of whole-body vibration exercise improves pain and fatigue in women with fibromyalgia. J Altern Complement Med. 2008;14:975-981.
74. da Silva GD, Lorenzi-Filho G, Lage LV. Effects of yoga and the addition of Tui Na in patients with fibromyalgia. J Altern Complement Med. 2007;13:1107-1113.
75. de Andrade SC, de Carvalho RF, Soares AS, et al. Thalassotherapy for fibromyalgia: a randomized controlled trial comparing aquatic exercises in sea water and water pool. Rheumatol Int. 2008;29:147-152.
76. Evcik D, Yigit I, Pusak H, et al. Effectiveness of aquatic therapy in the treatment of fibromyalgia syndrome: a randomized controlled open study. Rheumatol Int. 2008; 28:885-890.
77. Figueroa A, Kingsley JD, McMillan V, et al. Resistance exercise training improves heart rate variability in women with fibromyalgia. Clin Physiol Funct Imaging. 2008;28:49-54.
78. Fontaine K, Haaz S. Effects of lifestyle physical activity on health status, pain, and function in adults with fibromyalgia syndrome. J Muscoskel Pain. 2007;15:3-9.
79. Gusi N, Tomas-Carus P. Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial [Abstract]. Arthritis Res Ther. 2008;10:R24.
80. Haak T, Scott B. The effect of Qigong on fibromyalgia (FMS): a controlled randomized study. Disabil Rehabil. 2008;30:625-633.
81. Jones KD, Burckhardt CS, Deodhar AA, et al. A sixmonth randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. Arthritis Rheum. 2008;58:612-622.
82. Kayo A, Sanches C,Montegro-Rodrigues R, et al. Effectiveness of physical exercise on decrease of pain in patients with fibromyalgia [Abstract]. Arthritis Rheum. 2007;56:532.
83. Mannerkorpi K, Nordeman L, Ericsson A, et al. Pool exercise produces therapeutic effects in patients with fibromyalgia or chronic widespread pain. J Rehabil Med. 2009;41:751-760.
84. Matsutani LA, Marques AP, Ferreira EA, et al. Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia. Clin Exp Rheumatol. 2007;25:410-415.
85. Munguia-Izquierdo D, Legaz-Arrese A. Assessment of the effects of aquatic therapy on global symptomatology in patients with fibromyalgia syndrome: a randomized controlled trial. Arch Phys Med Rehabil. 2008;89: 2250-2257.
86. Rooks DS, Gautam S, Romeling M, et al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med. 2007;167:2192-11200
87. Stephens S, Feldman BM, Bradley N, et al. Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial. Arthritis Rheum. 2008;59:1399-1406.
88. Tomas-Carus P, Hakkinen A, Gusi N, et al. Aquatic training and detraining on fitness and quality of life in fibromyalgia. Med Sci Sports Exerc. 2007;39:1044-1050.
89. Tomas-CarusP, Gusi N, Hakkinen A, et al. Eight months of physical training in warm water improves physical and mental health inwomenwith fibromyalgia: a randomized controlled trial. J Rehabil Med. 2008;40:248-252.
90. Valkeinen H, Alen M, Hakkinen A, et al. Effects of concurrent strength and endurance training on physical fitness and symptoms in postmenopausal women with fibromyalgia: a randomized controlled trial. Arch Phys Med Rehabil. 2008;89:1660-1666.
91. van Santen M, Bolwijn P, Landewe R, et al. High or low intensity aerobic fitness training in fibromyalgia: does it matter? J Rheumatol. 2002;29:582-587.
92. Jones KD, Burckhardt CS, Clark SR, et al. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J Rheumatol. 2002;29:1041-1048.
93. Kingsley JD, Panton LB, Toole T, et al. The effects of a 12-week strength-training program on strength and functionality in women with fibromyalgia. Arch Phys Med Rehabil. 2005;86:1713-1721.
94. Bircan C, Karasel SA, Akgun B, et al. Effects of muscle strengthening versus aerobic exercise program in fibromyalgia. Rheumatol Int. 2008;28:527-532.
95. Hakkinen K, Pakarinen A, Hannonen P, et al. Effects of strength training on muscle strength, cross-sectional area, maximal electromyographic activity, and serum hormones in premenopausal women with fibromyalgia. J Rheumatol. 2002;29:1287-1295.
96. Hannonen P, Rahkita P, Kallinen M, et al. Effects of prolonged vs muscle strengthen programs on fibromyalgia [Abstract]. J Muscoskel Pain. 1995;70:34.
97. Valkeinen H, Hakkinen K, Pakarinen A, et al. Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia. Scand J Rheumatol. 2005;34:309-314.
98. Valkeinen H, Hakkinen A, Hannonen P, et al. Acute heavy-resistance exercise induced pain and neuromuscular fatigue in elderly women with fibromyalgia and in healthy controls: effects of strength training. Arthritis Rheum. 2006;54:1334-1349.
99. Martin L, Nutting A, MacIntosh BR, et al. An exercise program in the treatment of fibromyalgia. J Rheumatol. 1996;23:1050-1053.
100. McCain GA, Bell DA, Mai FM, et al. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum. 1988;31:1135-1141.
101. Richards SC, Scott DL. Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. BMJ. 2002;325:185.
102. Valim V, Oliveira L, Suda A, et al. Aerobic fitness effects in fibromyalgia. J Rheumatol. 2003;30:1060-1069.
103. Beck AT. Thinking and depression: theory and therapy. Arch Gen Psychiatry. 1964;10:561-571.
104. Thieme K, Flor H, Turk DC. Psychological pain treatment in fibromyalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments. Arthritis Res Ther. 2006;8:R121.
105. Vázquez-RiveraS,Gonzá lez-BlanchC,Rodriguez-MoyaL, et al. Brief cognitive-behavioral therapy with fibromyalgia patients in routine care. Compr Pstchiatry. 2009;50:517-525.
106. Williams DA, Cary MA, Groner KH, et al. Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol. 2002;29:1280-1286.
107. Allen LA, Woolfolk RL, Escobar JI, et al. Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial. Arch Intern Med. 2006;166: 1512-1518.
108. Burckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome. Pain in Adults and Children. APS Clinical Practice Guideline Series No 4. Glenview, IL: American Pain Society; 2005.
109. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromylagia syndrome. Ann Rheum Dis. 2008;67:536-541.
110. Klement A, Häuser W, Brückle W, et al. General principles of therapy, coordination of medical care and patient education in fibromyalgia syndrome and chronic widespread pain [in German]. Schmerz. 2008;22:283-294.